Feb

13

A Good Investment Potential in Healthcare Industry

Filed Under Medical Equipment & Supplies | 1 Comment

I’ve been watching this stock in the past 2 months and I have to tell you, I made right decision to add this one to my “stock-watch” list.. :)

Cambridge Heart Inc. (Symbol: CAMH) is a healthcare company, engaged in the research, development, and commercialization of products for the non-invasive diagnosis of cardiac disease. According to the information on their website, Cambridge Heart’s products incorporate its proprietary technology, Microvolt T-Wave Alternans, and are the first diagnostic tools cleared by the U.S. Food and Drug Administration to non-invasively measure microvolt levels of T-wave alternans.

Above is the graph of their stock perfomance in the past 3 months. When I started watching them (which was early in January), the stock was traded at $0.72/share. And now? It’s $1.45/share.

Even though their revenue has declined by 21.9% since last year ($1,089,200 in Q4 2005 vs. $1,394,800 in Q4 2004), but I firmly believe this company is going to be doing well this year since they’ve got good products to sell.

It is not easy to find a company who develop and sell good products, and whose stock is traded less than $5/share. I was pretty luck to come accross this one when I was doing my weekly stock research.

Quote of the Day:
It’s important to be able to make decisions without complete or perfect information. Things are almost never clear on Wall Street, or when they are, then it’s too late to profit from them. – Peter Lynch

  • Share/Bookmark

Feb

5

Amarin Corp plc (Symbol: AMRN)

Filed Under Biotechnology & Drugs | Leave a Comment

Amarin Corp plc is a neuroscience company focused on the research, development and commercialisation of novel drugs for the treatment of central nervous system disorders.

I’m still kicking myself for not buying this stock when I had a chance to. A month ago, I added this stock to my “Investment to Watch” List. At that time, the stock was traded at $1.95/share.

And now? It’s $3.32/share!!!

I gotta tell you, it’s really hard to find a cheap biotech stock. But I was pretty lucky finding this one. Had I bought 1,000 shares of it a month ago, I would’ve made $1,370 by now.

In the past few months, a lot of things have happened in the company. They announced $2 million equity investment by Dr. Tony Ryan (who is a Director of Ryanair Holdings and was a founder and former Chairman of GPA Group plc, an operating lessor of commercial aircraft. Dr. Ryan also served as Executive Chairman of GE Capital Aviation Services, Limited), preliminary results from Parkinson’s disease pre-clinical program using Miraxion (studies show that Miraxion has neuroprotective effects in Parkinson’s disease), they licensed Phase IIb/III Drug for the treatment of fatigue in multiple sclerosis to Multicell Inc., and they raised another $24 million in private placement.

Here’s how their price/share has been performing in the past 30 days:

What do you think, huh? This one is definitely a good investment.

As I said before, I’m still kicking myself for not getting this one a month earlier. On the other hand, it’s still not too late to invest your money in this company…

Quote of the Day:
Great investment opportunities come around when excellent companies are surrounded by unusual circumstances that cause the stock to be misappraised. – Warren Buffett

  • Share/Bookmark

ss_blog_claim=15d8108b540c7f0a9f388810cf5ad68f ss_blog_claim=15d8108b540c7f0a9f388810cf5ad68f